The post SNX Technical Analysis Mar 2 appeared on BitcoinEthereumNews.com. SNX, struggling in the grip of the daily downtrend while trapped around 0.31 dollars,The post SNX Technical Analysis Mar 2 appeared on BitcoinEthereumNews.com. SNX, struggling in the grip of the daily downtrend while trapped around 0.31 dollars,

SNX Technical Analysis Mar 2

For feedback or concerns regarding this content, please contact us at [email protected]

SNX, struggling in the grip of the daily downtrend while trapped around 0.31 dollars, a deep correction may be imminent if the critical 0.29 support line breaks – but the slight recovery in RSI, is it signaling a hidden buying opportunity?

Market Overview and Current Position

Synthetix’s native token SNX has fallen to 0.31 dollars with a 1.26% loss over the last 24 hours and is trading in a narrow range between 0.30-0.33. Although market volume remains stable at the 12.32 million dollar level, the downtrend pressure in the overall crypto ecosystem is challenging altcoins. Despite Bitcoin’s sideways movement around 66 thousand dollars, DeFi-focused tokens like SNX are among the most affected by liquidity shortages and the general decrease in risk appetite. In this position, although SNX’s short-term outlook is bearish, the identification of 8 strong levels in multi-timeframe confluence presents an intriguing dynamic for strategic traders.

On the daily timeframe, the trend is clearly downward; the price continues to stay below the EMA20 (0.34 dollars) and the Supertrend indicator is giving a bearish signal. On the weekly chart, however, 1W supports may come into play to support a potential base formation. With the recent calm news flow, price movements are entirely left to technical factors – this brings pure chart reading skills to the forefront. I recommend checking more detailed data for SNX spot analyses, as volume in the spot market is a critical indicator for an altcoin rally.

The overall market sentiment is cautious; as BTC dominance rises, altcoins are under pressure. SNX’s 0.31 level is functioning as a short-term consolidation point, but volume-less drops can deepen at any moment. In this context, traders can manage their positions by hedging through SNX futures.

Technical Analysis: Key Levels to Watch

Support Zones

The strongest support level stands out at 0.2916 dollars (score: 72/100); this level is one of the recent lows on the daily chart and forms a strong base in 1D timeframe confluence. If broken, the next critical zone at 0.2460 dollars (score: 68/100) comes into play – this line is reinforced by supports from 3D and 1W timeframes. In multi-timeframe analysis, 2 out of a total of 8 strong levels are supports (1D: 2S), preparing solid ground for a potential bounce. Looking at historical data, volume increases during tests of 0.2916 have triggered rebounds; traders should monitor this zone for long entries.

In a deeper scenario, the 0.2460 level carries psychological significance, and a break could quickly turn momentum downward. These supports represent oversold zones created by market fear, despite SNX’s utility in the DeFi ecosystem.

Resistance Barriers

The short-term first resistance is positioned at 0.3318 dollars (score: 68/100); aligned with the EMA20, this line is one of the 24-hour highs and a strong barrier on the daily chart. If it closes above, resistances at 0.3725 (score: 60/100) and 0.4453 (score: 62/100) could be tested – these are levels from 1D/1W confluence (total 3D:1R, 1W:3R). The Supertrend’s 0.42 resistance is on radars as a medium-term target; however, the current bearish structure makes reaching this area difficult.

The strength of resistances, combined with lack of volume, delays breakouts. In historical breakouts, surpassing 0.3318 has triggered 20% rallies – but the current low momentum limits this possibility.

Momentum Indicators and Trend Strength

RSI is hovering in a neutral-bearish region at 42.71; approaching oversold (below 30) could signal a rebound, but the current 42 band indicates continuing selling pressure. The MACD histogram is negative with a bearish crossover dominant, and the lack of divergence confirms trend strength. Short-term bearish alignment on EMAs (price below EMA20) continues, while the effects of the 50/200 EMA death cross are still felt.

Supertrend is in bearish mode, aligned with the 0.42 resistance; OBV shows weak declining volume trend. On multi-timeframe, 1W RSI near 35 shows slight recovery traces, carrying medium-term pivot potential. Overall trend strength is downtrend-focused, but slowing in momentum indicators may signal sideways consolidation.

Risk Assessment and Trading Outlook

When calculating the risk/reward ratio from current levels, bullish target 0.6460 (score:28) offers about 108% upside potential (~from 0.31), while bearish target 0.0460 (score:21) reaches 85% downside risk – a balanced picture, but downtrend dominance highlights short bias. With low volatility, sudden spikes should be expected; stop-losses should be positioned below supports (below 0.29). In a positive scenario, a 0.33 breakout triggers a rally; in negative, a 0.29 break brings a deep selling wave.

Outlook is cautiously bearish: A test of 0.29 is likely short-term, while a BTC recovery could lift SNX medium-term. Traders should manage risks tightly, as liquidity traps are common in altcoins.

Bitcoin Correlation

SNX moves in high correlation with BTC as an altcoin; BTC’s current downtrend (66,161 dollars, -0.87%) is directly pressuring SNX. BTC supports at 64,398, 62,468, and 60,000 dollars are critical – breaks of these lines would create a cascade effect on SNX toward 0.24. Conversely, if BTC resistances at 67,682, 69,989, and 74,487 dollars are surpassed, SNX could see a 0.37+ rally. With BTC Supertrend bearish, caution mode dominates for altcoins; SNX traders should watch BTC’s 64k support.

This analysis uses Chief Analyst Devrim Cacal’s market views and methodology.

Trading Analyst: Emily Watson

Short-term trading strategies expert

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/snx-technical-analysis-march-2-2026-support-resistance-and-market-commentary

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09